Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Imaging & Diagnostic Equipment
biomerieux.com

See what CB Insights has to offer

Investments

18

Portfolio Exits

7

Partners & Customers

10

About bioMerieux

bioMerieux (Paris:BIM), operates within the field of in vitro diagnostics, provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. The company's products are used for diagnosing infectious diseases and providing high medical value results for cancer screening, monitoring and cardiovascular emergencies.

bioMerieux Headquarter Location

100, Allee Louis Pasteur

Marcy L'Etoile, 69280,

France

0 820 22 3000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing bioMerieux

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find bioMerieux in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Infectious Disease

2,225 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

H

Health Monitoring & Diagnostics

701 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

bioMerieux Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

bioMerieux Rank

Latest bioMerieux News

Insights Clinical Diagnostics Automation Global Market to 2027 - Featuring Abaxis, Abbott Diagnostics and bioMerieux Among Others - ResearchAndMarkets.com

Oct 22, 2021

Amid the COVID-19 crisis, the global market for Clinical Diagnostics Automation estimated at US$4.1 Billion in the year 2020, is projected to reach a revised size of US$7.2 Billion by 2027, growing at a CAGR of 8.2% over the period 2020-2027. The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 12.4% CAGR The Clinical Diagnostics Automation market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 12.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR. Select Competitors (Total 52 Featured): Abaxis Inc. Recent Market Activity End-User and Technology-Led Aspects Drive Demand for Automation Key Factors Encouraging Laboratories to Adopt Automation - In a Nutshell Desire to Expand Bottom Lines Automation Liberates Patients from Risk of Pre-analytical Diagnostic Errors Lack of Skilled Workforce Rising Healthcare Costs and Pressing Need for Quality Testing Clinical Diagnostics Automation Insulate Effects of Tightening Labor Market Demographic Shifts & Societal Changes Drive Demand for Greater Clinical Care Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS Microplate instrumentation - An Integral Component of Lab Automation Market Modular Automation Surges Ahead of TLA in Adoption Automation Plays an Important Role in Patient Treatment Management Automation in Immunohistochemistry offers High Throughput Capabilities Demand for Automated Hematology Analyzers on Rise Technological Advancements Drive Growth in the Global Automated Biochemistry Analyzers Market Automated Multiplexing Technology and its Role in Clinical Diagnostics Automation Microbiology Laboratories Vie for Automation High-End Microplate Washers Offer Enhanced Capabilities Laboratory Information System - A Key Aspect of Clinical Diagnostics Automation Operational Concerns Associated with LIS Bar Code Technology Continues to Gain Adoption in Clinical Settings 4. GLOBAL MARKET PERSPECTIVE

bioMerieux Investments

18 Investments

bioMerieux has made 18 investments. Their latest investment was in Accellix as part of their Series D on June 6, 2020.

CBI Logo

bioMerieux Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/11/2020

Series D

Accellix

$9.5M

Yes

2

12/4/2017

Series B

Qvella

$20M

Yes

7

1/19/2017

Series A - V

Banyan Biomarkers

$7M

Yes

1

1/10/2014

Series C

Subscribe to see more

$99M

Subscribe to see more

10

11/16/2012

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/11/2020

12/4/2017

1/19/2017

1/10/2014

11/16/2012

Round

Series D

Series B

Series A - V

Series C

Series C

Company

Accellix

Qvella

Banyan Biomarkers

Subscribe to see more

Subscribe to see more

Amount

$9.5M

$20M

$7M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

7

1

10

10

bioMerieux Portfolio Exits

7 Portfolio Exits

bioMerieux has 7 portfolio exits. Their latest portfolio exit was BioTheranostics on January 05, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/5/2021

Acquired

$991

17

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

1/5/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

17

10

10

10

10

bioMerieux Acquisitions

10 Acquisitions

bioMerieux acquired 10 companies. Their latest acquisition was Hybiome Biomedical on June 06, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/6/2019

Corporate Majority

Corporate Majority - II

1

2/7/2019

Unattributed

$991

$17.51M

Acquired

4

11/9/2018

Corporate Majority

$991

Corporate Majority

2

4/4/2018

Series F

Subscribe to see more

$991

$99M

Subscribe to see more

10

1/21/2016

Loan

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/6/2019

2/7/2019

11/9/2018

4/4/2018

1/21/2016

Investment Stage

Corporate Majority

Unattributed

Corporate Majority

Series F

Loan

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$17.51M

$99M

$99M

Note

Corporate Majority - II

Acquired

Corporate Majority

Subscribe to see more

Subscribe to see more

Sources

1

4

2

10

10

bioMerieux Partners & Customers

10 Partners and customers

bioMerieux has 10 strategic partners and customers. bioMerieux recently partnered with Specific Diagnostics on June 6, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

6/29/2021

Licensor

Specific Diagnostics

United States

bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL® Rapid AST system in Europe

bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL ® Rapid AST system in Europe

3

10/8/2020

Partner

Africa Medical Supplies Platform

Rwanda

Africa Medical Supplies Platform AMSP partners with BioMérieux to facilitate supply of high-quality COVID-19 diagnostics

We have been working relentlessly to expand choice & quality of supplies and that is why this partnership with bioMérieux is very important to us , '' said African Union Special Envoy , Strive Masiyiwa .

1

3/26/2020

Partner

Novartis, Pfizer, Sanofi, Boehringer Ingelheim, Bd Biosciences, Eisai, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co., and Merck KGaA

Switzerland, United States, France, Germany, Japan, and United Kingdom

Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundation

Basel , March 26 , 2020 -- Today , Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development , manufacture and delivery of vaccines , diagnostics , and treatments for COVID-19 in response to the pandemic .

5

1/4/2020

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

11/18/2019

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/29/2021

10/8/2020

3/26/2020

1/4/2020

11/18/2019

Type

Licensor

Partner

Partner

Vendor

Partner

Business Partner

Specific Diagnostics

Africa Medical Supplies Platform

Novartis, Pfizer, Sanofi, Boehringer Ingelheim, Bd Biosciences, Eisai, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co., and Merck KGaA

Country

United States

Rwanda

Switzerland, United States, France, Germany, Japan, and United Kingdom

Subscribe to see more

Subscribe to see more

News Snippet

bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL® Rapid AST system in Europe

bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL ® Rapid AST system in Europe

Africa Medical Supplies Platform AMSP partners with BioMérieux to facilitate supply of high-quality COVID-19 diagnostics

We have been working relentlessly to expand choice & quality of supplies and that is why this partnership with bioMérieux is very important to us , '' said African Union Special Envoy , Strive Masiyiwa .

Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundation

Basel , March 26 , 2020 -- Today , Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development , manufacture and delivery of vaccines , diagnostics , and treatments for COVID-19 in response to the pandemic .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

1

5

10

10

bioMerieux Team

11 Team Members

bioMerieux has 11 team members, including former Chief Executive Officer, Christopher R Hibberd.

Name

Work History

Title

Status

Christopher R Hibberd

Chief Executive Officer

Former

Albert A Luderer

President, Chief Operating Officer

Former

Laurent Amat

Chief Financial Officer

Former

Stéphane Guerido

Chief Financial Officer

Former

Laurent Thiery

Sanofi Pasteur

Chief Financial Officer

Former

Name

Christopher R Hibberd

Albert A Luderer

Laurent Amat

Stéphane Guerido

Laurent Thiery

Work History

Sanofi Pasteur

Title

Chief Executive Officer

President, Chief Operating Officer

Chief Financial Officer

Chief Financial Officer

Chief Financial Officer

Status

Former

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.